Christine D. Baker - 16 Sep 2022 Form 4 Insider Report for TYME TECHNOLOGIES, INC.

Role
Director
Signature
By: /s/ Richard Cunningham as attorney-in-fact for Christine D. Baker
Issuer symbol
N/A
Transactions as of
16 Sep 2022
Net transactions value
$0
Form type
4
Filing time
16 Sep 2022, 18:00:31 UTC
Previous filing
29 Aug 2022
Next filing
18 Apr 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TYME Director Stock Option - Option to buy Disposed to Issuer -14,666 -100% 0 16 Sep 2022 Common Stock 14,666 $0.3500 Direct F1
transaction TYME Director Stock Option - Option to buy Disposed to Issuer -36,888 -100% 0 16 Sep 2022 Common Stock 36,888 $0.3500 Direct F2
transaction TYME Director Stock Option - Option to buy Disposed to Issuer -88,000 -100% 0 16 Sep 2022 Common Stock 36,888 $0.3100 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Christine D. Baker is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 This award consisted of options to purchase 176,000 shares of Tyme common stock, 14,666 of which had vested as of the date of the merger between the issuer and Syros Pharmaceuticals, Inc ("Syros"). The vested portion was assumed by Syros in the merger and replaced with an option to purchase 642 shares of Syros common stock for $7.99 per share, after giving effect to a 1-for-10 reverse stock split by Syros (the "Reverse Split"). The remaining unvested portion of the option award was cancelled upon the reporting person's resignation from the board in connection with the merger, pursuant to the terms of the award.
F2 This option was fully vested and assumed by Syros in the merger and replaced with an option to purchase 1,616 shares of Syros common stock for $7.99 per share, after giving effect to the Reverse Split.
F3 This option was fully vested and assumed by Syros in the merger and replaced with an option to purchase 3,856 shares of Syros common stock for $7.07 per share, after giving effect to the Reverse Split.